CA3123252C - Stable anti-cxcr5 igg4 antibody formulations - Google Patents

Stable anti-cxcr5 igg4 antibody formulations Download PDF

Info

Publication number
CA3123252C
CA3123252C CA3123252A CA3123252A CA3123252C CA 3123252 C CA3123252 C CA 3123252C CA 3123252 A CA3123252 A CA 3123252A CA 3123252 A CA3123252 A CA 3123252A CA 3123252 C CA3123252 C CA 3123252C
Authority
CA
Canada
Prior art keywords
antibody
formulation
cxcr5
light
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3123252A
Other languages
English (en)
French (fr)
Other versions
CA3123252A1 (en
Inventor
Julia Schnieders
Dirk Usener
Ahmed YOUSSEF
Annika Hagendorf
Martina KIRSCH
Sabrina RUGGEBERG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Priority to CA3204402A priority Critical patent/CA3204402A1/en
Publication of CA3123252A1 publication Critical patent/CA3123252A1/en
Application granted granted Critical
Publication of CA3123252C publication Critical patent/CA3123252C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA3123252A 2012-03-26 2013-03-26 Stable anti-cxcr5 igg4 antibody formulations Active CA3123252C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3204402A CA3204402A1 (en) 2012-03-26 2013-03-26 Stable anti-cxcr5 igg4 antibody formulations

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261615539P 2012-03-26 2012-03-26
US61/615,539 2012-03-26
FR1351013 2013-02-06
FR1351013 2013-02-06
CA2868401A CA2868401C (en) 2012-03-26 2013-03-26 Stable anti-cxcr5 igg4 antibody formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2868401A Division CA2868401C (en) 2012-03-26 2013-03-26 Stable anti-cxcr5 igg4 antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3204402A Division CA3204402A1 (en) 2012-03-26 2013-03-26 Stable anti-cxcr5 igg4 antibody formulations

Publications (2)

Publication Number Publication Date
CA3123252A1 CA3123252A1 (en) 2013-10-03
CA3123252C true CA3123252C (en) 2023-08-22

Family

ID=49261390

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3123252A Active CA3123252C (en) 2012-03-26 2013-03-26 Stable anti-cxcr5 igg4 antibody formulations
CA2868401A Active CA2868401C (en) 2012-03-26 2013-03-26 Stable anti-cxcr5 igg4 antibody formulations
CA3204402A Pending CA3204402A1 (en) 2012-03-26 2013-03-26 Stable anti-cxcr5 igg4 antibody formulations

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2868401A Active CA2868401C (en) 2012-03-26 2013-03-26 Stable anti-cxcr5 igg4 antibody formulations
CA3204402A Pending CA3204402A1 (en) 2012-03-26 2013-03-26 Stable anti-cxcr5 igg4 antibody formulations

Country Status (7)

Country Link
EP (3) EP4527855A3 (https=)
JP (1) JP6265970B2 (https=)
BR (2) BR122019026701B1 (https=)
CA (3) CA3123252C (https=)
PL (1) PL2830658T3 (https=)
RU (1) RU2644214C2 (https=)
WO (1) WO2013148686A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3297653T (lt) 2015-05-22 2022-01-10 The Board Of Trustees Of The Leland Stanford Junior University Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais
GB201608323D0 (en) * 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
CN107446044B (zh) * 2016-05-30 2021-04-30 越海百奥药业(绍兴)有限公司 一种纯化抗体的方法及所用缓冲液
CN115998858A (zh) 2016-07-05 2023-04-25 赛诺菲 抗体制剂
TWI760345B (zh) * 2016-07-05 2022-04-11 法商賽諾菲公司 抗體調配物
KR20190079662A (ko) * 2016-11-11 2019-07-05 바이엘 악티엔게젤샤프트 연속적 유동 내의 오염물을 모니터링하기 위한 유체 스트림의 샘플링 방법
LT3541366T (lt) * 2016-11-21 2025-03-10 Amylyx Pharmaceuticals, Inc. Eksendino (9-39) buferiniai preparatai
GB201701194D0 (en) 2017-01-24 2017-03-08 Capella Bioscience Ltd Antigen binding molecules that bind light
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
BR112019018022A2 (pt) * 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
US11312781B2 (en) 2018-01-24 2022-04-26 Capella Bioscience Ltd. Antigen binding molecules that bind LIGHT
JP2024502825A (ja) * 2020-12-30 2024-01-23 エーマックス バイオ， インコーポレイテッド 抗体の局所的延長放出

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2966592B2 (ja) * 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CN101721362B (zh) * 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
US8658773B2 (en) * 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
DK2236154T3 (en) * 2003-02-10 2018-06-25 Biogen Ma Inc IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
WO2006042333A2 (en) 2004-10-12 2006-04-20 Xencor, Inc. Prediction and assessment of immunogenicity
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2007074880A1 (ja) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
AR060487A1 (es) * 2006-04-21 2008-06-18 Xoma Technology Ltd Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
AU2007290570C1 (en) 2006-08-28 2013-08-15 Kyowa Kirin Co., Ltd. Antagonistic human LIGHT-specific human monoclonal antibodies
CL2007003583A1 (es) * 2006-12-11 2008-07-18 Hoffmann La Roche Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
MX338397B (es) 2007-08-29 2016-04-15 Sanofi Aventis Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.

Also Published As

Publication number Publication date
EP2830658A2 (en) 2015-02-04
WO2013148686A3 (en) 2013-11-28
CA2868401C (en) 2021-08-24
BR122019026701B1 (pt) 2023-01-24
CA3204402A1 (en) 2013-10-03
WO2013148686A2 (en) 2013-10-03
JP6265970B2 (ja) 2018-01-24
JP2015514090A (ja) 2015-05-18
BR112014023952B1 (pt) 2023-01-24
RU2014142990A (ru) 2016-05-20
BR112014023952A2 (pt) 2017-07-18
CA3123252A1 (en) 2013-10-03
EP4527855A3 (en) 2025-06-11
EP3431104A1 (en) 2019-01-23
PL2830658T3 (pl) 2019-02-28
EP4527855A2 (en) 2025-03-26
RU2644214C2 (ru) 2018-02-08
CA2868401A1 (en) 2013-10-03
EP2830658B1 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
CA3123252C (en) Stable anti-cxcr5 igg4 antibody formulations
US10525130B2 (en) Stable IGG4 based binding agent formulations
CA2649538C (en) Buffering agents for biopharmaceutical formulations
US20110256135A1 (en) Anti-nerve growth factor (ngf) antibody compositions
AU2017293103B2 (en) Antibody formulations
US12139533B2 (en) Liquid formulations of anti-CD200 antibodies
TWI860741B (zh) Pvrig/tigit雙特異性抗體藥物組合物及其用途
JP6820823B2 (ja) 安定なＩｇＧ４に基づく結合剤の製剤
JP2026514048A (ja) 抗ｏｘ４０ｌ抗体を含有する医薬製剤
WO2025185555A1 (en) Pharmaceutical compositions comprising ox40 targeting antibodies and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210920

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250321

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250321

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250321

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260312

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260312